Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,346 result(s) found. Displaying page 16 of 2,218.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    EudraCT Number: 2016-004702-34 Sponsor Protocol Number: CLS001-CO-PR-015 Start Date*: 2017-01-09
    Sponsor Name:Cutanea Life Sciences
    Full Title: A randomized, evaluator-blinded, vehicle-controlled study to explore the pharmacodynamic effects of omiganan and omiganan in combination with imiquimod in healthy volunteers.
    Medical condition: None
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10062249 Skin inflammation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000416-15 Sponsor Protocol Number: GS-US-342-2104 Start Date*: 2016-07-14
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects with Chronic HCV Infection who have Received a Liver Transp...
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    19.0 10019805 - Hepatobiliary disorders 10019754 Hepatitis cholestatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001831-38 Sponsor Protocol Number: ENB-009-10 Start Date*: 2017-05-09
    Sponsor Name:Alexion Pharma GmbH
    Full Title: A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, and Pharmacokinetics of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline...
    Medical condition: Hypophosphatasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005495-19 Sponsor Protocol Number: RVT-101-2001 Start Date*: 2016-06-13
    Sponsor Name:Axovant Sciences Inc.
    Full Title: A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB).
    Medical condition: Dementia with Lewy Bodies
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003962-24 Sponsor Protocol Number: 6632-9050-04 Start Date*: 2016-12-27
    Sponsor Name:Medice Arzneimittel Pütter GmbH & Co. KG
    Full Title: A multi-centre, randomized, placebo-controlled, double-blind, parallel-group study investigating safety and efficacy of a sore throat lozenge in the symptomatic treatment of patients with acute pha...
    Medical condition: Acute Pharyngitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002281-46 Sponsor Protocol Number: NN7008-4304 Start Date*: 2018-02-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: Safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with moderate or severe Haemophilia A in India.
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002266-71 Sponsor Protocol Number: GN14RE146 Start Date*: 2015-01-02
    Sponsor Name:NHS Greater Glasgow and Clyde
    Full Title: The role of Qutenza (topical capsaicin 8%) in treating neuropathic pain from arteriovenous fistulae in patients with end stage renal failure
    Medical condition: Chronic neuropathic pain from arteriovenous fistulae in patients with end stage renal failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004657-89 Sponsor Protocol Number: BIOS-16-001 Start Date*: 2020-12-14
    Sponsor Name:Ethicon Inc
    Full Title: A Prospective Study Evaluating the Safety and Effectiveness of EVARREST® Fibrin Sealant Patch in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open, Abdominal, Retr...
    Medical condition: Mild or moderate hepatic parenchyma or soft tissue bleeding during open, abdominal, retroperitoneal, pelvic and thoracic (non-cardiac) surgery
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002996-91 Sponsor Protocol Number: CB8025-21629 Start Date*: 2017-02-21
    Sponsor Name:CymaBay Therapeutics, Inc.
    Full Title: An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an in...
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003408-29 Sponsor Protocol Number: 5F9003 Start Date*: 2019-11-04
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
    Medical condition: Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029624 Non-Hodgkin's lymphoma unspecified histology indolent stage III PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029601 Non-Hodgkin's lymphoma refractory PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029623 Non-Hodgkin's lymphoma unspecified histology indolent stage II PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029622 Non-Hodgkin's lymphoma unspecified histology indolent stage I PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-000406-38 Sponsor Protocol Number: DEX-09-08 Start Date*: 2017-02-27
    Sponsor Name:Hospira Inc
    Full Title: A Phase II/III, Open-Label, Multicenter, Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Neonates Ages ≥ 28 Weeks to ≤ 44 Weeks Gestational Age
    Medical condition: Initially intubated and mechanically ventilated preterm neonates ≥ 28 weeks through < 36 weeks gestational age and term neonates born at ≥ 36 weeks through ≤ 44 weeks gestational age in an intens...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002449-71 Sponsor Protocol Number: LP0084-1193 Start Date*: 2015-12-23
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest including 12-month follow-up Part 1: 3-day treatment period including an 8-week follow-up period Part 2:...
    Medical condition: Actinic Keratosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001278-13 Sponsor Protocol Number: PROSIBD Start Date*: 2016-06-08
    Sponsor Name:Taina Sipponen
    Full Title: Immunologic, genetic and microbiomic predictors of the treatment response for TNFalpha-blocking drugs – prospective follow-up cohort of patients with Crohn’s disease or ulcerative colitis
    Medical condition: Ulcerative colitis and Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    19.0 10017947 - Gastrointestinal disorders 10013099 Disease Crohns LLT
    19.0 10017947 - Gastrointestinal disorders 10058815 Crohn's disease acute episode LLT
    19.0 10017947 - Gastrointestinal disorders 10057035 Crohn's ileocolitis LLT
    19.0 10017947 - Gastrointestinal disorders 10011405 Crohn's enteritis LLT
    19.0 10017947 - Gastrointestinal disorders 10011406 Crohn's ileitis LLT
    19.0 10017947 - Gastrointestinal disorders 10076318 Crohn's disease relapse LLT
    19.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    19.0 10017947 - Gastrointestinal disorders 10011402 Crohn's disease (colon) LLT
    19.0 10017947 - Gastrointestinal disorders 10075466 Fistulising Crohn's disease LLT
    19.0 10017947 - Gastrointestinal disorders 10066678 Acute ulcerative colitis LLT
    19.0 10017947 - Gastrointestinal disorders 10075465 Fistulizing Crohn's disease LLT
    19.0 10017947 - Gastrointestinal disorders 10011400 Crohn's colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001826-33 Sponsor Protocol Number: NA-1-007 Start Date*: 2017-07-07
    Sponsor Name:NoNO Inc.
    Full Title: A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects with Acute Ischemic Stroke Und...
    Medical condition: Acute Ischemic Stroke (AIS) in adult subjects with a large intracranial arterial occlusion, a small ischemic core, and good collaterals.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10055221 Ischemic stroke LLT
    20.1 10029205 - Nervous system disorders 10074321 Nonhaemorrhagic stroke LLT
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.0 10029205 - Nervous system disorders 10023027 Ischaemic stroke NOS LLT
    20.1 10029205 - Nervous system disorders 10074318 Nonhemorrhagic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004047-20 Sponsor Protocol Number: NN1250-4419 Start Date*: 2018-08-28
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, cross-over, open-label, multi-centre trial comparing the effect of insulin degludec and insulin glargine 100U/mL, with or without OADs in subjects with type 2 diabetes using flash glu...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2018-002532-24 Sponsor Protocol Number: 0155/2018 Start Date*: 2018-12-27
    Sponsor Name:HELM AG
    Full Title: A phase III, multicentre, randomised, double-blind, parallel-group trial to evaluate the efficacy and safety of a generic gel (calcipotriol + betamethasone 50 μg/g + 0.5 mg/g gel) compared to origi...
    Medical condition: mild to moderate plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000700-26 Sponsor Protocol Number: 178-CL-203 Start Date*: 2015-09-23
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A multicentre, open-label, single dose, phase 1 study to evaluate the pharmacokinetics, safety and tolerability of mirabegron oral suspension in pediatric subjects from 3 to less than 12 years of a...
    Medical condition: -neurogenic detrusor overactivity (NDO) -overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004857 10012547 Detrusor hyperreflexia LLT
    19.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003658-34 Sponsor Protocol Number: 9732 Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital of Montpellier
    Full Title: Non-inferiority of intranasal fentanyl versus oral morphine sulfate in the treatment of pain in pediatric trauma : a controled randomized , single blind study
    Medical condition: traumatic pain
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004066-28 Sponsor Protocol Number: AMLSG2415 Start Date*: 2018-04-04
    Sponsor Name:University Hospital Ulm
    Full Title: A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplas...
    Medical condition: Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome wi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001067-23 Sponsor Protocol Number: PasHypo Start Date*: 2018-05-07
    Sponsor Name:Zealand University Hospital
    Full Title: Pasireotide in the treatment of hypoglycemia following gastric bypass surgery
    Medical condition: Postprandial reactive hypoglycemia in patients with prior Roux-en-Y gastric bypass surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10059038 Postprandial hypoglycemia LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 01 20:08:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA